Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

EHA 2020 | Long-term safety of momelotinib for myelofibrosis

Claire Harrison • 5 Jun 2020
EHA 2020
Myelofibrosis Myeloproliferative Neoplasms Momelotinib Ruxolitinib

Claire Harrison, MD, DM, FRCP, FRCPath, of Guy’s and St Thomas’ NHS Foundation Trust, London, UK, outlines the long-term safety of momelotinib in myelofibrosis patients. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Claire Harrison

Preliminary results with nuvisertib plus momelotinib in patients with R/R myelofibrosis
1:26
Preliminary results with nuvisertib plus momelotinib in patients with R/R myelofibrosis
Claire Harrison • 8 Dec 2025
Safety & efficacy of INCA033989, a first-in-class mutant CALR-specific mAb, in patients with ET & MF
2:06
Safety & efficacy of INCA033989, a first-in-class mutant CALR-specific mAb, in patients with ET & MF
Claire Harrison • 8 Dec 2025
Real-world data on the treatment of adolescents and young adults with MPNs
2:49
Real-world data on the treatment of adolescents and young adults with MPNs
Claire Harrison • 23 Jun 2025
Evolving strategies in MPNs: big data analysis, wearable devices, & targeted therapies
3:20
Evolving strategies in MPNs: big data analysis, wearable devices, & targeted therapies
Claire Harrison • 23 Jun 2025

Related Videos

Guidance for selecting between JAK inhibitors in the frontline and second-line setting for MF
1:26
Guidance for selecting between JAK inhibitors in the frontline and second-line setting for MF
Claire Harrison • 6 Dec 2025
An overview of ongoing Phase III trials investigating novel treatment options for myelofibrosis
1:40
An overview of ongoing Phase III trials investigating novel treatment options for myelofibrosis
Claire Harrison • 6 Dec 2025
The management of patients with ET or PV during pregnancy
3:32
The management of patients with ET or PV during pregnancy
Claire Harrison • 7 Dec 2025
Preliminary analysis of the FEDORA trial: fedratinib plus ropeginterferon alfa-2b in myelofibrosis
2:37
Preliminary analysis of the FEDORA trial: fedratinib plus ropeginterferon alfa-2b in myelofibrosis
Claire Harrison • 7 Dec 2025
The content of VJHemOnc is intended for healthcare professionals